Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art

Systemic lupus erythematosus: Withdrawing standard of care therapies in SLE trials?

(2017) Chi Chiu Mok   Nature Reviews Rheumatology

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

(2017) Megan E. B. Clowse et al.   Arthritis & Rheumatology

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

(2016) Munther Khamashta et al.   ANNALS OF THE RHEUMATIC DISEASES

LB0001 Efficacy and Safety of Subcutaneous Belimumab plus Standard Care in Patients with Systemic Lupus Erythematosus (SLE) with Low Complement and Positive Anti-DSDNA:

(2016) A. Doria et al.   ANNALS OF THE RHEUMATIC DISEASES

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)

(2016) Ronald van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

AB0412 Exploratory Results from The Bliss and Illuminate Trials Support The Design of The CHABLIS-SC1 Trial, A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy and Safety of Blisibimod Administration in Subjects with Systemic Lupus Erythematosus: Table 1.

(2016) J.T. Merrill et al.   ANNALS OF THE RHEUMATIC DISEASES

Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients

(2016) Morton Scheinberg et al.   CLINICAL RHEUMATOLOGY

Update on clinical trials in systemic lupus erythematosus

(2016) Sonali Narain et al.   CURRENT OPINION IN RHEUMATOLOGY

Systemic lupus erythematosus: still a challenge for physicians

(2016) A. A. Bengtsson et al.   JOURNAL OF INTERNAL MEDICINE

The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials

(2016) B H Rovin et al.   LUPUS

Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?

(2016) K C Kalunian   LUPUS

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care

(2016) I N Bruce et al.   LUPUS

Plasma cells as an innovative target in autoimmune disease with renal manifestations

(2016) Falk Hiepe et al.   Nature Reviews Nephrology

Towards new avenues in the management of lupus glomerulonephritis

(2016) C. C. Mok   Nature Reviews Rheumatology

Con: The use of calcineurin inhibitors in the treatment of lupus nephritis: Table 1

(2016) Maria Fernandez Nieto et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis

(2016) Chi Chiu Mok   NEPHROLOGY DIALYSIS TRANSPLANTATION

Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study

(2016) Julie Ducreux et al.   RHEUMATOLOGY

Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study

(2016) D. J. Wallace et al.   ARTHRITIS CARE & RESEARCH

Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus

(2016) Luca Iaccarino et al.   ARTHRITIS CARE & RESEARCH

Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL

(2016) Caroline Gordon et al.   Arthritis & Rheumatology

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis

(2016) Brad H. Rovin et al.   Arthritis & Rheumatology

Treat-to-target in systemic lupus erythematosus: are we there yet?

(2016) Chi Chiu Mok   Expert Review of Clinical Pharmacology

Multitarget Therapy for Induction Treatment of Lupus Nephritis

(2015) Zhihong Liu et al.   ANNALS OF INTERNAL MEDICINE

Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty?: Table 1

(2015) Frédéric A Houssiau et al.   ANNALS OF THE RHEUMATIC DISEASES

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

(2015) Tobias Alexander et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

(2015) J T Merrill et al.   ANNALS OF THE RHEUMATIC DISEASES

Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)

(2015) Kate Franklyn et al.   ANNALS OF THE RHEUMATIC DISEASES

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

(2015) Kenneth C Kalunian et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

(2015) D A Isenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus

(2015) Thomas Dörner et al.   AUTOIMMUNITY REVIEWS

Epigenetics and Systemic Lupus Erythematosus: Unmet Needs

(2015) Pier Luigi Meroni et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Targeting Interferons in Systemic Lupus Erythematosus: Current and Future Prospects

(2015) Alexis Mathian et al.   DRUGS

Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices

(2015) J. S. Hui-Yuen et al.   JOURNAL OF RHEUMATOLOGY

Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis

(2015) Chandra Mohan et al.   Nature Reviews Nephrology

Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis

(2015) Francesca Pierotti et al.   PLoS One

LB0003 A Randomized Controlled Study of Laquinimod in Active Lupus Nephritis Patients in Combination with Standard of Care

(2014) D. Jayne et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study

(2014) R A Furie et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

(2014) David Isenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up

(2014) Chi Chiu Mok et al.   ANNALS OF THE RHEUMATIC DISEASES

Emerging biological therapies for systemic lupus erythematosus

(2014) Chi Chiu Mok   EXPERT OPINION ON EMERGING DRUGS

The role of dead cell clearance in the etiology and pathogenesis of systemic lupus erythematosus: dendritic cells as potential targets

(2014) Mona HC Biermann et al.   Expert Review of Clinical Immunology

Belimumab for the treatment of systemic lupus erythematosus

(2014) Natasha Jordan et al.   Expert Review of Clinical Immunology

Current role of rituximab in systemic lupus erythematosus

(2014) Chi Chiu Mok   International Journal of Rheumatic Diseases

Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient

(2014) Y. Wang et al.   RHEUMATOLOGY

Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

(2014) Maria Lucia Specchia et al.   Biomed Research International

Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study

(2014)   Arthritis & Rheumatology

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids

(2013) Marie B Condon et al.   ANNALS OF THE RHEUMATIC DISEASES

Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials

(2013) Vibeke Strand et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

(2013) Daniel J Wallace et al.   ANNALS OF THE RHEUMATIC DISEASES

Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials

(2013) Michelle A. Petri et al.   ARTHRITIS AND RHEUMATISM

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study

(2013) Eduardo F. Mysler et al.   ARTHRITIS AND RHEUMATISM

Sifalimumab, a Human Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study

(2013) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab

(2013) E. A. Rossi et al.   BLOOD

Targeting the complement system in systemic lupus erythematosus and other diseases

(2013) Maria-Louise Barilla-LaBarca et al.   CLINICAL IMMUNOLOGY

Bortezomib for the treatment of previously untreated multiple myeloma

(2013) Alessandra Romano et al.   Immunotherapy

Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus

(2013) E. M. Ginzler et al.   JOURNAL OF RHEUMATOLOGY

Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment

(2013) Grainne Murphy et al.   LANCET

Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID)

(2013) M Witt et al.   LUPUS

Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study

(2013) CC Mok et al.   LUPUS

Epratuzumab for Systemic Lupus Erythematosus

(2013) DJ Wallace et al.   LUPUS

Belimumab for Systemic Lupus Erythematosus

(2013) Bevra Hannahs Hahn   NEW ENGLAND JOURNAL OF MEDICINE

The Tolerogenic Peptide, hCDR1, Down-Regulates the Expression of Interferon-α in Murine and Human Systemic Lupus Erythematosus

(2013) Zev Sthoeger et al.   PLoS One

Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus

(2013) L. Quartuccio et al.   RHEUMATOLOGY

B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design

(2013) Venkat Reddy et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve-Month, Randomized, Double-Blind Study

(2013) Richard Furie et al.   Arthritis & Rheumatology

Regulatory cell subsets in the control of autoantibody production related to systemic autoimmunity

(2012) Keishi Fujio et al.   ANNALS OF THE RHEUMATIC DISEASES

Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus

(2012) Yuko Shirota et al.   ANNALS OF THE RHEUMATIC DISEASES

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

(2012) Robert Zimmer et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

(2012) Susan Manzi et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study

(2012) Jacqueline M. McBride et al.   ARTHRITIS AND RHEUMATISM

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

(2012) William Stohl et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

(2012) Brad H. Rovin et al.   ARTHRITIS AND RHEUMATISM

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus

(2012) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Disease Mechanisms in Rheumatology-Tools and Pathways: Plasmacytoid Dendritic Cells and Their Role in Autoimmune Rheumatic Diseases

(2012) Maija-Leena Eloranta et al.   ARTHRITIS AND RHEUMATISM

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid

(2012) Bernard R. Lauwerys et al.   ARTHRITIS AND RHEUMATISM

Type I IFN system in the development and manifestations of SLE

(2012) Keith B. Elkon et al.   CURRENT OPINION IN RHEUMATOLOGY

Abatacept for systemic lupus erythematosus: the outlook

(2012) Chi Chiu Mok   EXPERT OPINION ON BIOLOGICAL THERAPY

BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus

(2012) Kirsten Fairfax et al.   IUBMB LIFE

Peptide-based approaches to treat lupus and other autoimmune diseases

(2012) Nicolas Schall et al.   JOURNAL OF AUTOIMMUNITY

Neutrophil Extracellular Traps That Are Not Degraded in Systemic Lupus Erythematosus Activate Complement Exacerbating the Disease

(2012) J. Leffler et al.   JOURNAL OF IMMUNOLOGY

Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial

(2012) W. WINN CHATHAM et al.   JOURNAL OF RHEUMATOLOGY

Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study

(2012) A Fernández-Nebro et al.   LUPUS

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

(2012) DJ Wallace et al.   LUPUS

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE

(2012) MA Dooley et al.   LUPUS

Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis

(2012) Marc Weidenbusch et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial

(2012) Ellen M Ginzler et al.   ARTHRITIS RESEARCH & THERAPY

The PROMISE Study: A Phase 2b Multicenter Study of Voclosporin (ISA247) Versus Tacrolimus in De Novo Kidney Transplantation

(2011) S. Busque et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Active immunisation of human interferon   transgenic mice with a human interferon   Kinoid induces antibodies that neutralise interferon   in sera from patients with systemic lupus erythematosus

(2011) A. Mathian et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon   monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

(2011) J. T. Merrill et al.   ANNALS OF THE RHEUMATIC DISEASES

B cell biomarkers of rituximab responses in systemic lupus erythematosus

(2011) Edward M. Vital et al.   ARTHRITIS AND RHEUMATISM

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells

(2011) H. Travis Ichikawa et al.   ARTHRITIS AND RHEUMATISM

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts

(2011) Cándido Díaz-Lagares et al.   AUTOIMMUNITY REVIEWS

Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside

(2011) William Stohl et al.   CURRENT OPINION IN RHEUMATOLOGY

Belimumab

(2011) Celeste B. Burness et al.   DRUGS

Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE

(2011) Matthew M. Seavey et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Systemic Lupus Erythematosus

(2011) George C. Tsokos   NEW ENGLAND JOURNAL OF MEDICINE

Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA-Peptide Complexes in Systemic Lupus Erythematosus

(2011) R. Lande et al.   Science Translational Medicine

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

(2010) J. T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

(2010) J.-E. Gottenberg et al.   ARTHRITIS AND RHEUMATISM

Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry

(2010) Benjamin Terrier et al.   ARTHRITIS AND RHEUMATISM

Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

(2010) Gabor G. Illei et al.   ARTHRITIS AND RHEUMATISM

Update on emerging drug therapies for systemic lupus erythematosus

(2010) Chi Chiu Mok   EXPERT OPINION ON EMERGING DRUGS

Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells

(2010) Clemens Scheinecker et al.   JOURNAL OF AUTOIMMUNITY

Epidemiology and survival of systemic lupus erythematosus in Hong Kong Chinese

(2010) CC Mok   LUPUS

Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases

(2010) J. Cortes-Hernandez et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis

(2010) A. Hakkim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes)

(2010) William Stohl   ARTHRITIS RESEARCH & THERAPY

The role of dendritic cells in the pathogenesis of systemic lupus erythematosus

(2010) Justin H Fransen et al.   ARTHRITIS RESEARCH & THERAPY

Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study

(2009) Jason W. Bauer et al.   ARTHRITIS AND RHEUMATISM

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

(2009) Daniel J. Wallace et al.   ARTHRITIS AND RHEUMATISM

Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study

(2009) Annett M. Jacobi et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Genetics of systemic lupus erythematosus and Sjögrenʼs syndrome

(2009) R Hal Scofield   CURRENT OPINION IN RHEUMATOLOGY

Abetimus sodium: a medication for the prevention of lupus nephritis flares

(2009) Diane M Horowitz et al.   EXPERT OPINION ON PHARMACOTHERAPY

The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients

(2009) Zev M. Sthoeger et al.   HUMAN IMMUNOLOGY

CTLA4Ig Alters the Course of Autoimmune Disease Development in Lyn-/- Mice

(2009) S. A. Oracki et al.   JOURNAL OF IMMUNOLOGY

Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases

(2009) M Ramos-Casals et al.   LUPUS

The Pathophysiologic Role of Monocytes and Macrophages in Systemic Lupus Erythematosus: A Reappraisal

(2009) Christina G. Katsiari et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

(2008) D Albert et al.   ANNALS OF THE RHEUMATIC DISEASES

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

(2008) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: Results of an early phase II clinical trial

(2008) Sylviane Muller et al.   ARTHRITIS AND RHEUMATISM

Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial

(2008) Mario H. Cardiel et al.   ARTHRITIS AND RHEUMATISM

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

(2008) Kirsten Neubert et al.   NATURE MEDICINE

Proteasome inhibition: a new therapeutic option in lupus nephritis?

(2008) J. van der Vlag et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

(2008) Richard Furie et al.   ARTHRITIS RESEARCH & THERAPY

Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus

(2007) M Nikpour et al.   ANNALS OF THE RHEUMATIC DISEASES